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Recommendations on chronic diseases management emphasise the need to consider
patient perspectives and shared decision-making. Discrepancies between patients and phy-
sicians’ perspectives on treatment objectives, disease activity, preferences and treatment
have been described for immune-mediate inflammatory diseases. These differences could
result on patient dissatisfaction and negatively affect outcomes.
Objective
To describe the degree of patient-physician discrepancy in three chronic immune-mediated
inflammatory diseases (rheumatoid arthritis [RA], psoriatic arthritis [PsA] and psoriasis
[Ps]), identifying the main areas of discrepancy and possible predictor factors.
Methods
Qualitative systematic review of the available literature on patient and physician discrepan-
cies in the management of RA, PsA and Ps. The search was performed in international
(Medline/PubMed, Cochrane Library, ISI-WOK) and Spanish electronic databases
(MEDES, IBECS), including papers published from April 1, 2008 to April 1, 2018, in English
or Spanish, and conducted in European or North American populations. Study quality was
assessed by the Oxford Centre for Evidence-Based Medicine criteria.
Results
A total of 21 studies were included (13 RA; 3 PsA; 4 Ps; 1 RA, Ps, and Axial Spondyloarthri-
tis). A significant and heterogeneous degree of discrepancy between patients and
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physicians was found, regarding disease activity, treatment, clinical expectations, remission
concept, and patient-physician relationship. In RA and PsA, studies were mainly focused
on the evaluation of disease activity, which is perceived as higher from the patient’s than
the physician’s perspective, with the discrepancy determined by factors such as patient’s
perception of pain and fatigue. In Ps, studies were focused on treatment satisfaction and
patient-physician relationship, showing a lower degree of discrepancy in the satisfaction
regarding these aspects.
Conclusions
There is a significant degree of patient-physician discrepancy regarding the management of
RA, PA, and Ps, what can have a major impact on shared decision-making. Future research
may help to show whether interventions considering discrepancy improve shared decision-
making.
Introduction
Immune-mediated inflammatory diseases, including rheumatoid arthritis (RA), psoriatic
arthritis (PsA) and psoriasis (Ps), are a group of chronic and highly disabling conditions that
share common inflammatory pathways [1]. They affect millions of individuals worldwide,
with a prevalence of 5%–7% in the Western society [1].
Recommendations for the treatment of chronic diseases emphasise the need to work in
partnership with the patient [2]. For rheumatic diseases in particular, such as RA or PsA, the
assessment of disease activity, as well as therapeutic decisions, rely heavily on patient-reported
outcomes in combination with the physician’s perception, in contrast to other fields of medi-
cine in which treatment decisions are based on measurable biomarkers [3]. Patient reported
outcomes are reliable measures that allow the translation of qualitative clinical impressions
into quantitative data [4,5]. They have shown to be as effective as physician-reported results or
clinical variables in reflecting changes in disease activity over time [6]. In the case of dermato-
logical diseases, such as Ps, several studies and clinical practice guidelines highlight the need to
include both, the objective evaluation of severity and the subjective perception of the disease
impact on the patient, for disease assessment [7], which is not routinely estimated [8].
In clinical practice, patient and physician perspective regarding disease state and treatment
expectations may differ. Discrepancies in the assessed health status may result in patient dissat-
isfaction and could negatively affect patient care, treatment compliance and disease outcomes,
with the consequent cost to society [2,9].
The literature about the differences between patients and physicians’ perspectives regarding
the management of their disease is heterogeneous, and the potential predictors of the discrep-
ancy are not clear [2]. The objective of this systematic review is to describe the degree of dis-
crepancy between patients and physicians in the management of three immune-mediated
inflammatory diseases (RA, PsA and Ps), identifying the main areas of discrepancy and the
possible predictor factors.
Methods
A qualitative systematic review of the literature on the existing differences between patients
and physicians’ perspective in the management of RA, PsA and Ps was conducted according to
PRISMA recommendations [10].
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To identify relevant articles, targeted literature searches in international (Medline/PubMed,
Cochrane Library, ISI Web of knowledge [ISI WOK]) and Spanish electronic databases (Medi-
cina en Español [MEDES], Índice Bibliográfico Español en Ciencias de la Salud [IBECS]) were
conducted. The search strategy was focused on the conditions of interest, the physician and
patient figures, and terms related to discrepancy between them (S1 Table). Reference lists of the
selected articles were hand-searched to identify additional potentially relevant publications.
The search was limited to studies published in English or Spanish, from April 1, 2008 to
April 1, 2018. Studies that focused on the discrepancy between patients and physicians in the
management of RA, PsA and Ps, conducted in Europe or North America (or international
publications comprising European or North American populations) were included. We
excluded congress abstracts, study protocols, letters to the editor and those publications
reviewed in the systematic review included in our review.
After removal of duplicates, the records were screened by two independent researchers, in
two levels. The first level included title or abstract screening, and the second level included full
text screening. Discrepancies were reviewed by a third researcher and resolved by consensus.
The included studies were graded on quality of evidence according to the Oxford Centre for
Evidence-Based Medicine (OCEBM) criteria [11], where level 1 is the maximum level of evi-
dence (e.g. systematic reviews) and level 5 is the minimum level of evidence (e.g. expert opin-
ion). Risk of bias was measured though a Newcastle-Ottawa scale adapted for cross-sectional
studies [12,13], where the maximum score is 10, and the minimum is 0, considering a low
risk of bias 7 points or more, and high risk of bias 6 points or less. Risk of bias for systematic
reviews was measured through ROBIS tool, which classifies the studies in high, low or unclear
risk of bias [14].
General data were extracted from each publication, including country, design, disease stud-
ied, participants, and the level of evidence. The variables of discrepancy were identified in each
publication (discrepancy definition, measurement tools, and results) and grouped according
to the disease. Predictor factors of discrepancy (measurement tools and results) were summa-
rized for each publication.
Results
A total of 718 titles were identified. Of them, 20 publications were relevant to the objective of
the study and, therefore, were selected. An additional record from references’ review was iden-
tified, hence 21 articles were finally included in the review (Fig 1). The general characteristics
of the 21 studies reviewed are summarized in Table 1. Main results (discrepancy and predictor
factors) for each study are shown in Table 2, and described further (discrepancy definition,
measurement tools, detailed results) in S2 Table. Excluded publications based on the selection
criteria are shown in S3 Table.
Characteristics of the selected studies
Disease. Thirteen (62%) articles evaluated the differences between patients and physi-
cians’ perspectives on RA, 3 (14%) on PsA, and 4 (19%) on Ps. One article (5%) included
patients with different diseases (RA, PsA, and Axial Spondyloarthritis [axSpA]).
Country. Forty-three percent of the studies (n = 9) included were conducted in the USA,
38% (n = 8) in Europe (Belgium, Netherlands, Denmark, Spain, UK and European Union), 5%
(n = 1) in Canada, and 14% (n = 3) were conducted internationally.
Design. Ninety-five percent of the studies (n = 20) were observational. Of these, 24%
(n = 5) followed a retrospective, 14% (n = 3) a prospective, and 57% (n = 12) a cross-sectional
design. The remaining publication (5%) was a systematic review with meta-analysis.
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Level of evidence and risk of bias. Using the Oxford Centre for Evidence-Based Medicine
criteria, the quality of evidence was graded. Sixty-seven percent of the studies were graded 2c
(n = 14), 5% (n = 1) of studies had level 2a, 10% (n = 2) level 4, and the remaining 19% (n = 4)
had level 5. Therefore, the included studies would have a B-D recommendation grade.
Risk of bias measured through Newcastle-Ottawa scale showed that 62% (n = 13) of the
studies had low risk of bias (7 points or more), and 33% (n = 7) had a high risk of bias (6 points
or less), with four of those studies being qualitative. The remaining 5% (n = 1) was measured
with ROBIS scale for systematic reviews and showed a low risk of bias (S4 Table and S1 Fig).
Discrepancy area. Sixty-two percent of the studies (n = 13) focused on disease activity,
24% (n = 5) on treatment, 10% (n = 2) on patient-physician relationship (one of the articles
evaluated discrepancies in both treatment and patient-physician relationship), 5% (n = 1)
focused on the clinical visit expectations, and 5% (n = 1) on the concept of remission.
1. Rheumatoid arthritis
Disease activity assessment. Sixty-nine percent (n = 9) of the RA studies included evalu-
ated the discrepancies in disease activity assessment [2,16,18–20,22–24,26].
Five of them included RA general patients and used the Patient and Physician Global
Assessments (PtGA and PhGA, respectively) questionnaires [2,16,19,22,24]. The degree of
discrepancy found in these studies ranged between 25% [2] and 76,0% [2]. The majority of
patients reported higher values than physicians in the overall assessment, indicating a greater
perception of disease activity from the patient’s perspective (defined as positive discrepancy,
PD). On the other hand, to a lesser extent, cases of negative discrepancy (ND) were described,
where the physician’s assessment indicated higher disease activity than the patient’s self-
assessment. Four studies evaluated the predictor factors of patient-physician discrepancy
[2,16,19,22], finding that the discrepancy observed was mainly influenced by the Tender Joint
Count (TJC) and Swollen Joint Count (SJC), pain, fatigue, general health (GH) and the onset
of depressive symptoms. Some studies described a variation of the discrepancy, either accord-
ing to the patients’ disease activity or over time. Two studies showed poorer agreement in
patients with higher RA activity, compared to those in remission or with low RA activity
[16,24]. Another one reported a decrease in discrepancy over time (from 31.8% at baseline to
Fig 1. Study selection flowchart according to PRISMA.
https://doi.org/10.1371/journal.pone.0234705.g001
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Table 1. Characteristics of the 21 studies included in the systematic review.
Author, year Country Study design Discrepancy area Study participants Level of
evidence
RHEUMATOID ARTHRITIS
Acebes et al. [15],
2017
Spain Cross-sectional Remission concept 5 RA patients 5
18 rheumatologists (6 involved in basic research, 6
with high specialisation in imaging techniques and 6
clinical rheumatologists)
Challa et al. [16],
2017
USA Cross-sectional Disease activity
assessment
350 patients with RA or rheumatoid polyarthritis 2c
Healthcare professionals (physician, fellow, nurse
practitioner, physician assistant) �
De Mits et al. [17],
2016








12 studies including 11.879 RA patients Physicians� 2a
















536 patients with stable RA Rheumatologists� 2c
Kvrgic et al. [20],
2017
USA Cross-sectional Disease activity
assessment
20 RA patients with patient-physician discrepancy 5
Markenson et al.
[21], 2013
USA Retrospective Treatment 4.359 RA patients Rheumatologists� 2c









763 RA patients Physicians� 2c
Walter et al. [23],
2017
Netherlands Cross-sectional Disease activity
assessment
29 RA patients with patient-physician discrepancy 5






206 patients with active RA 2c
4 rheumatologists






270 RA patients 4
111 physicians
Wolfe et al. [26],
2009
USA Cross-sectional Disease activity
assessment
800 RA patients 4
Rheumatologists�
PSORIASIS
Daudén et al. [27],
2011
Spain Cross-sectional Treatment Patient-
Physician
Relationship




United Kingdom Cross-sectional Treatment 174 patients 2c
100 dermatologists
Korman et al. [29],
2016














460 PsA patients 2c
Physicians�
Eder et al. [3], 2015 Canada Cross-sectional Disease activity
assessment
565 PsA patients 2c
Rheumatologists�
Furst et al. [32],
2017
USA Retrospective Disease activity
assessment
305 paired rheumatologists and PsA patient records 2c
(Continued)
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27.2% at 36 weeks of treatment) and found an association between higher discrepancy and
worse clinical outcomes (TJC, SJC, pain, Clinical Disease Activity Index [CDAI], Simple Dis-
ease Activity Index [SDAI], GH) [22] (Table 2). Additionally, one study examined the impact
of PD and its persistence on health-related quality of life (HRQoL) and work productivity on
final visit, finding that higher patient ratings (PD) at any time in the study (baseline visit, 1
year, 2 years) were associated with worse HRQoL, work productivity and activity impairment
on final visit, compared with patients who did not present PD [19].
Three out of the nine studies evaluated patient-physician discrepancy in disease activity
assessment in RA patients in remission [18,22,26]. Although the procedures used and the
definition of remission varied among the studies, results showed that, in general, patients
and physicians had different perceptions regarding disease activity. Thus, the number of
patients in remission was lower from the patient perspective than from the physician per-
spective (Table 2).
Two out of the nine studies explored the factors that patients considered relevant for the
PD in disease activity [20,23]. Through focus groups interviews, seven themes came out: per-
ceived stress, balancing activities and rest, medication intake, social stress, relationship with
professionals, comorbidity, and physical fitness [23]. From patient interviews, six major
themes emerged: being misunderstood by others, limitations of provider assessments, discrep-
ancy with provider findings, inadequate active listening on the part of health care providers,
unmet psychosocial needs, and lack of patient empowerment [20] (Table 2).
Treatment. Fifteen percent (n = 2) of the RA studies evaluated the discrepancies regard-
ing treatment.
One of them assessed patient and physician satisfaction with biological medications in
relation to the control of disease symptoms and the route of administration [17]. The results
showed a higher patient satisfaction with both symptom control and route of administration,
compared to physicians (p<0.001), regardless of the route of administration. The physician’s
perception of patient’s satisfaction with disease control was markedly lower for intravenous
treated patients as opposed to subcutaneous treated patients (p< 0.001). The second study
evaluated the discrepancy in the perceived therapeutic effectiveness of Disease Modifying
Antirheumatic Drugs (DMARD). PtGA and PhGA were similar at baseline, but in the follow-
up assessments, a worse evaluation for DMARD effectiveness was found from the patients’
perspective, compared to the physicians [21].
Clinical visit expectations. Eight percent (n = 1) of the RA studies focused on patient-
physician discrepancy over the expectations during the clinical visit [25]. The study compared
the expectations of patients and physicians about what was most important to achieve during a
rheumatology clinic visit. Both agreed on their main expectation: pain control. Expectations
from the patients’ perspective were pain control (63.7%), improvement of function (49.3%)
and discussion of effect of medication (38.1%). From physicians’ perspective, the main
Table 1. (Continued)
Author, year Country Study design Discrepancy area Study participants Level of
evidence
RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS
Lindström Egholm
et al. [33], 2015
Denmark Retrospective Disease activity
assessment
10.282 patients (8.300 RA patients, 1.458 PsA patients
and 524 axSpA patients)
2c
90 physicians (50% were specialists)
� Number of physicians not specified; ^ Quality of evidence graded according to the Oxford Centre for Evidence-Based Medicine criteria
https://doi.org/10.1371/journal.pone.0234705.t001
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Table 2. Discrepancy and predictor factors in rheumatoid arthritis, psoriatic arthritis and psoriasis.
Author, year Results
RHEUMATHOID ARTHRITIS. Discrepancy area: DISEASE ACTIVITY ASSESSMENT
Karpouzas et al. [19], 2017 Discrepancy: 43% (PD: 31.3%; ND: 11.7%).
Predictor factors. PD: higher fatigue, pain, HAQ-DI, lower TJC and SJC, and worse
GH (p<0.02); ND: lower pain, higher TJC and SJC and PHQ-9 (p<0.01).
Challa et al. [16], 2017 Discrepancy: 32.5% (PD: 29.5%; ND: 2.1%).
Predictor factors (OR, 95% CI): Diagnosis of fibromyalgia 3.06 (1.87–8.00);
depression 1.79 (1.02–3.15); lack of articular erosions 0.56 (0.32–0.97).
Desthieux et al. [2], 2016 Discrepancy: 43% (95% CI: 36%-51%; range: 25%-76%); (PD: 34%; ND: 9%).
Predictor factors: pain; TJC/SJC; higher levels of depressive symptoms; health
literacy.
Ward et al. [24], 2017 Discrepancy: lower with rating scale vs. PhGA (p<0.0001) (PtGA—PhGA: 8.5 ±
22.4; Rating scale—PhGA: 2.3 ± 24.0)^
Smolen et al. [22], 2016 General patients:
• Discrepancy. Baseline: PD 25.5%, ND: 6.3%; week 36 of etanercept
+ methotrexate treatment: PD 24.8%, ND: 2.4%.
• Predictor factors:
• Baseline factors correlated with 36-week discrepancy (r<0.25, p<0.05). Directly
correlated: BPI, duration of morning stiffness and GH; Inversely correlated:
fatigue, and SJC.
• Factors measured in week 36. Moderate correlation: BPI, GH (r = 0.48 y r = 0.58,
respectively, p<0.0001). Weak correlation (r<0.25, p<0.0001): directly correlated:
DAS28, duration of morning stiffness, HAQ-DI, CDAI y SDAI; inversely
correlated: fatigue.
• Factors measured at baseline predicting the discrepancy at week 36 (OR, 95% CI):
BPI 1.22 (1.11–1.35), CRP 0.98 (0.97–1.00) and GH 1.02 (1.00–1.03).
Discrepancy in remission patients. Remission according to clinical and Boolean
criteria (PD: 0%; DN: 2.0%); according to clinical but not Boolean criteria (PD:
49.2%; DN: 1.1%); according to CDAI (PD: 7.8%; DN: 1.0%).
Wolfe et al. [26], 2009 Patients discordant with their physicians: 21.4%; patients concordant with their
physicians: 78.6% (K: 0.54, 95% CI: 0.45–0.58)
Janta et al. [18], 2013 Discrepancy regarding the percentage of patients in remission. According to
DAS28: 26.1% (patients) vs. 52.2% (physicians) (p<0.0005); according SDAI:
14.5% (patients) vs. 11.6% (physicians) (p = 0.172)
Kvrgic et al. [20], 2017 Predictive factors of discrepancy from patients’ perspective: Being misunderstood by
others; Limitations of physician assessments; Discrepancy with physicians’ findings;
Inadequate active listening by doctors; Unmet psychosocial needs; Lack of patient
empowerment during clinical visits.
Walter et al. [23], 2017 Predictive factors of discrepancy (PD) in disease activity from patients’ perspective: 1)
perceived stress, 2) balancing activities and rest, 3) medication intake, 4) social stress,
5) relationship with professionals, 6) comorbidity, and 7) physical fitness.
RHEUMATHOID ARTHRITIS. Discrepancy area: TREATMENT
De Mits et al. [17], 2016 Satisfaction with symptom control: 44% of satisfied patients vs. 35% of satisfied
physicians [OR = 3.9 (2.6 ± 5.8); p < 0.001].
Satisfaction with route of administration. IV route: 52.4% of satisfied patients vs.
29.9% of satisfied physicians (p<0.001); SC route: 56.2% of satisfied patients vs.
45.5% of satisfied physicians (p<0.001).
Markenson et al. [21], 2013 Baseline: similar PtGA and PhGA scores (5.90 vs. 5.85); 5 years follow-up: PtGA
higher than PhGA (between 4.05–4.46 for PtGA vs. 2.74–3.76 for PhGA)^.
RHEUMATHOID ARTHRITIS. Discrepancy area: CLINICAL VISIT EXPECTATIONS
Wen et al. [25], 2012 Patient’ main expectations: pain control (63.7%); improvement of function (49.3%);
discussion about the effect of medication (38.1%).
Physician’ main expectations: pain control (59.5%), inquiry about drug side-effects
(47.8%); objective assessment of disease activity (41.4%).
(Continued)
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Table 2. (Continued)
Author, year Results
RHEUMATHOID ARTHRITIS. Discrepancy area: REMISSION CONCEPT
Acebes et al. [15], 2017 Rheumatologists: highlighted quantifiable objective parameters.
Patients: preferred subjective measures of remission (need of finding a new definition
of remission, new assessment tools that consider their feelings and all the symptoms
they suffer).
PSORIATIC ARTHRITIS. Discrepancy area: DISEASE ACTIVITY
Eder et al. [3], 2015 Discrepancy. Joint activity: 32.8% (PD: 31.2%, ND: 1.6%); Skin activity: 22.2% (PD:
15.4%, ND: 6.8%).
Predictor factors. Joint activity: fatigue (21.3%), TJC (16.3%), pain (9.2%), and SJC
(1.5%); Skin activity: pain (17.3%), DLQI (14%) and PASI (11.8%).
Desthieux et al. [31], 2017 Discrepancy: 29.1% (PD: 25.0%, ND: 4.1%); Discordant patients in remission: 30.8%;
discordant patients with high disease activity: 26.1%
Predictor factors (higher discrepancy): higher fatigue, lower self-perceived coping
and impaired social participation.
Furst et al. [32], 2017 Discrepancy: 23.6% (satisfied patient- dissatisfied physician: 17.0%; dissatisfied
patient—satisfied physician: 6.6%)
Predictor factors: SJC (p = 0.020), HAQ-DI (p = 0.025)
PSORIASIS. Discrepancy area: TREATMENT
Korman et al. [29], 2016 Discrepancy: 18,4% (in 70.4% of cases, patient was satisfied, and physician
dissatisfied).
Daudén et al. [27], 2011 No significant discrepancies on treatment satisfaction and treatment compliance
between physicians and patients were observed (p>0,05).
Gonzalez et al. [28], 2016 Discrepancies: 1) Improvements in plaques on limbs were more important than
plaques on the torso for physicians, but not for patients; 2) Patients perceived a
significant benefit in reducing mild plaque area from 10% to 0%, but not physicians;
3) Patients perceived the impact of an area of 10% very severe plaques to be much
more important than dermatologists; 4) Dermatologists valued improvements in very
severe plaques for areas greater than 10%, but patients were insensitive to changes in
the affected area beyond 10%; 5) Dermatologists were more sensitive to 10%
lymphoma risk in the next 10 years than patients.
Maximum Acceptable Risk: higher in patients than in physicians.
PSORIASIS. Discrepancy area: PATIENT-PHYSICIAN RELATIONSHIP
Daudén et al. [27], 2011 No significant differences were observed: 1) Almost all patients and physicians
considered their relationship was good or very good (96.4% vs. 96%, respectively); 2)
Patients had a good opinion about the physician (98% vs 95.2%); 3) Patients were
satisfied with the treatment received (92% vs 94.7%); 4) Patients were satisfied with
the time spent by the specialist (97.1% vs 92.2%).
Uhlenhake et al. [30], 2010 Patients required more information about Ps, fast-acting treatments, clear
expectations, and recognition of the emotional burden.
Physicians considered that patients do not internalize information adequately and
need more information about treatments.
RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS. Discrepancy
area: DISEASE ACTIVITY ASSESSMENT
Lindström Egholm et al.
[33], 2015
Discrepancy. RA: 49% (PD: 47.1%, ND: 1.9%); PsA: 56.5% (PD: 56.2%, ND: 0.3%);
axSpA: 48.3% (PD: 46.9%, ND: 1.4%)
Predictor factors (higher discrepancy). RA (higher discrepancy): patient female sex,
older age, lower SJC and higher TJC, higher CRP, treatment with biologics; PsA:
lower SJC and higher TJC; AxSpA: patient female sex, treatment with biologics
PD: positive discrepancy; ND: negative discrepancy; PtGA: patient global assessment; PhGA: physician global
assessment; DAS: Disease Activity Score; HAQ-DI: Health assessment questionnaire disability index; TJC: tender
joint count; SJC: swollen joint count; GH: general health; CDAI: Clinical Disease Activity Index; SDAI: Simple
Disease Activity Index; BPI: Brief Pain Inventory; CRP: C-Reactive Protein; CI: confidence interval; IV: intravenous;
SC: subcutaneous; DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area Severity Index; RA: Rheumatoid
Arthritis; PsA: Psoriatic Arthritis; axSpA: Axial Spondyloarthritis; OR: odds ratio. ^Higher PtGA and PhGA denote
worse assessments.
https://doi.org/10.1371/journal.pone.0234705.t002
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expectations were pain control (59.5%), inquiry about drug side-effects (47.8%) and objective
assessment of disease activity (41.4%). The main difference between patients and physicians
was in the importance of the objective assessment of disease activity, which was prioritized by
physicians, but not by patients.
Remission concept. Eight percent (n = 1) of the RA studies focused on patient-physician
discrepancy over the concept of remission itself [15]. The results showed a discrepancy
between patients and physicians, as well as among physicians themselves. Rheumatologists
highlighted quantifiable objective parameters, while patients preferred subjective measures of
remission, pointing out the need of finding a new definition of remission and new assessment
tools that consider what they feel and the wide range of symptoms they suffer. Nonetheless,
many rheumatologists agreed with patients that a new definition of remission should consider
two concepts: psychosocial variables and the context. On the other hand, physicians disagreed
among themselves on the value given to the different parameters to diagnose remission. While
some of them were in favour of seeking an objective definition of remission with the assistance
of some type of instrument, others safeguarded a subjective point of view in which each patient
has his own point of disease remission.
2. Psoriatic arthritis
Three of the articles included in the review evaluated the differences between patients and
physicians’ perspectives on PsA regarding disease activity [3,31,32]. Two of them focused on
disease activity in general [3,31], while the third one evaluated the discrepancy over the satis-
faction with the control of disease activity [32]. The three studies evaluated additionally the
predictor factors or factors affecting the discrepancy.
Results revealed a PD (patients indicated more severe disease) between patients and physi-
cians. This discrepancy was greater for the assessment of joint activity (31.2%) than for skin
activity (15.4%). To a lesser extent, a ND (patients indicated more less severe disease) was
observed: 1.6% in the assessment of the joints and 6.8% for the skin [3]. Discrepancy was
greater in patients in remission (30.8%), compared to patients with high disease activity
(26.1%) [31]. In general, PsA patients were satisfied with the control of their disease activity.
Patient-physician discrepancy regarding this satisfaction was 23.6%, mainly explained by the
dissatisfaction of physicians with the control of their patients’ disease [32]. Misaligned patients
reported greater work impairment, assessed with Work Productivity Activity Impairment
index (work impairment, mean 38.7 vs. 21.4, P = 0.0004; presentism, mean 36.2 [25.3] vs. 16.5
[21.2], P< 0.0001; and daily activities, mean, 38.7 vs. 22.3, P< 0.0001), and higher disease
burden (mean Health Assessment Questionnaire-Disability Index [HAQ-DI] 0.56 vs. 0.37,
P = 0.0001), compared to those patients aligned with their physicians [32].
Fatigue and pain were the main predictor factors of the discrepancy between patients and
physicians [3,31]. A higher SJC and HAQ-DI score predicted greater patient-physician dis-
crepancy in relation to satisfaction with disease control [32].
3. Psoriasis
Four of the articles selected in the review evaluated the differences between patients and physi-
cians perspectives on Ps [27–30].
Treatment. Seventy-five percent (n = 3) of Ps studies evaluated the discrepancies regard-
ing treatment [27–29]. One of them focused exclusively on treatment satisfaction [29], another
on treatment satisfaction and compliance [27], and the third evaluated patient-physician pref-
erences for the outcomes of Ps treatments [28].
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Patient-physician discrepancy regarding satisfaction with the treatment for Ps was 18.4%,
where in 70.4% of the cases the physicians were dissatisfied, and patients were satisfied. Mis-
alignment was associated with increased disease and symptom severity, poorer HRQoL, and
reduced work productivity. Additionally, patients in the misaligned group were, on average,
more recently diagnosed than those in the aligned group [21].
Discrepancy regarding compliance with treatment was not present. The perception of
patient HRQoL affectation was very similar between patients and physicians, with no discrep-
ancy between them. According to dermatologists, 56.4% of patients had a high or moderate
physical impairment and 63.8% had a high or moderate emotional impairment; while these
assessments made by the patients amounted to 56.5% and 60.5%, respectively [27].
In reference to treatment preferences, patients and physicians differed in which symp-
toms they preferred to improve and in the importance of the risk of adverse events. Derma-
tologists perceived improvements in plaques on limbs were more important than plaques on
the torso, while there were no differences in patients. However, patients perceived a signifi-
cant benefit in reducing mild plaque area from 10% to 0%, while dermatologists didn’t.
Similarly, an area of 10% of very severe plaques had a greater impact for patients than for
dermatologists. Dermatologists valued improvements in very severe plaques for areas greater
than 10%, while patients were insensitive to changes in the affected area beyond 10%, but
were more sensitive to a 10% lymphoma risk in the next 10 years than patients. Additionally,
compared to physicians, patients were generally more willing to assume a risk of adverse
events in exchange for clinical benefits, although this difference was only significant for
clearance of very severe plaques [28].
Patient-physician relationship. Fifty percent (n = 2) of Ps studies assessed the discrepan-
cies in patient-physician relationship [27,30], being one of them focused on communication
issues [30]. An agreement between patients and physicians was found regarding their percep-
tion of the relationship with the doctor, opinion about the doctor, satisfaction with the treat-
ment received by the doctor, and satisfaction with the time the doctor dedicates to the patient
[27]. However, a disagreement was found in patient-physician communication regarding
compliance issues, treatment plan preferences and goals, education, and emotional burden
[30].
4. Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis
One of the studies included in the review evaluated the frequency of patient-physician discrep-
ancy over disease activity assessment in patients with RA, PsA or axSpA, and investigated
whether a greater discrepancy in female patients (compared to male patients) was associated
with physicians’ gender [33].
Results showed a patient-physician discrepancy in approximately 50% of cases. Male
patients had lower odds of discordance compared with female patients across all 3 diagnoses,
although not statistically significantly in PsA. Lower SJC and higher TJC increased the odds of
discrepancy in RA and PsA. Older patients with RA had slightly higher odds of discordance.
Patients who were not treated with biologicals tended to have lower odds of discordance.
Discussion
Compared to other diseases, such as diabetes or hypertension, where an objective and numeri-
cal measurement to assess disease severity and treatment response is available (hemoglobin
A1c or blood pressure), the lack of a single gold standard measurement to assess disease activ-
ity in immune-mediated inflammatory diseases difficult its management, pointing out the
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need to consider both objective and subjective assessments [34]. Moreover, taking into
account patients perspective and involving them in disease activity assessment may enhance
self-management behaviour and ultimately improve health outcomes [35].
The studies reviewed show that patients and physicians focus on different aspects of the dis-
ease, resulting in different perceptions of disease severity, diverse clinical expectations or dif-
ferent impressions of treatment response. In immune-mediated inflammatory diseases, these
discrepancies are associated with worse clinical outcomes, activity impairment, reduction in
work productivity and poorer HRQoL [19,21,22,32]. Previous studies have reported that dis-
cordance is also associated with a lower likelihood of remission in patients with RA and PsA
[36]; greater joint destruction and functional impairment in RA [37], and higher Disease
Activity Score (DAS28) and C-Reactive Protein (CRP) after the 24 weeks of disease-modifying
therapy in early RA [38]. This association between discrepancy and worse clinical outcomes
has also been described in other diseases such as asthma [39].
This systematic review denotes that the literature addressing patient-physician discrepancy
in RA, PsA and Ps is very heterogeneous and highlights the lack of a standardized criterion to
define discrepancy, with patients and physicians’ perspectives appraised using diverse tools,
and discrepancy established according to different cut-off values. This circumstance results in
different degrees of discrepancy according to the criteria considered and makes it difficult to
compare results between studies. In this regard, an inverse correlation between the frequency
of discrepancy and the cut-off point used has been previously reported in the literature, being
the discrepancy higher when the cut-off point is lower [2].
Differences among immune-mediated inflammatory diseases have been detected. Thus, the
studies conducted in RA and PsA were mainly focused on the evaluation of disease activity,
while studies performed in Ps were focused on treatment satisfaction and preferences, and on
patient-physician relationship.
In RA, PtGA-PhGA discrepancy about disease activity assessment varied among studies,
ranging from 25% to 76%. In general, it was lower in patients in remission, and greater in
patients with moderate or high disease activity. Patient and physician disagreement has been
previously reported [34,40–42] and, in many cases, may adversely affect therapeutic decisions
[43] and the assessment of treatment response [41]. The discrepancy could be explained in
part, since patients could rely more heavily on the subjective perception of pain and discom-
fort, and therefore discrepancy will not only reflect the disease status but also psychological
distress and comorbidities [21,44]. Additionally, another study in RA concluded that physi-
cians underestimated disease severity and treatment related adverse events and their impact
on patient perceived well-being [45]. Physicians are generally more prone to use objective
measures to determine treatment response and may not pay sufficient consideration to
patient-reported variables [21]. Accordingly, expectations during the clinical visit also differed
on the objective assessment of disease activity in RA, which was prioritized by physicians,
but not by patients, although both, patients and physicians, shared the same objective: pain
control [25]. Previous studies have reported that RA patients have higher expectations from
their treatment than physicians, specifically in terms of pain control [46]. Finally, in relation
to satisfaction with disease treatment, RA patients receiving biologics generally revealed better
satisfaction about the control of the symptoms, regardless of the route of administration, while
physicians consistently considered IV biological therapy to be less satisfactory. Even though
the factors associated with the discrepancy in RA have not been well established [47], our
results show that major factors affecting PtGA-PhGA discrepancy in disease activity assess-
ment are TJC, SJC, fatigue and pain. The awareness of which factors contribute to physicians’
and patients’ perceptions may help to define an improved standard measurement to better
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assess disease activity and treatment response, and to establish an enhanced patient-physician
dialogue [21,47].
In line with previous studies conducted in PsA [21], a greater PD for joint activity (31.2%)
compared to skin activity (15.4%) was observed. This discrepancy was predicted mainly by
fatigue and pain. At present, there is an increasing trend to rely on patient self-reported ques-
tionnaires of disease activity and treatment response for monitoring patient status and adjust-
ing treatment if necessary [35]. Therefore, according to our results, as patient self-report does
not agree with physician observation, to rely solely on patient self-reported joint counts may
not be appropriate [48], or vice-versa, suggesting the need to use both objective and subjective
measurements. Our results indicate that, contrary to RA, discrepancy was greater in patients
in remission, compared with high disease activity patients.
In Ps, low discrepancies were detected related to treatment satisfaction in Ps or patient phy-
sician relationship. Patient physician relationship is key to achieve a high-quality health care,
as it has been described that many doctors tend to overestimate their ability in communication
and that much patient dissatisfaction and complaints are due to breakdown in the doctor-
patient relationship [49]. Nonetheless, some patient-physician differences were found regard-
ing treatment preferences, objectives, compliance or emotional burden. Accordingly, despite
previous communications reporting different perceptions between psoriasis patients and
their physicians with respect to disease severity, symptoms, disease control [50] or treatment
goals [51], the results of this review suggest improvement in the dialogue between patient and
physician.
This qualitative systematic review has several limitations. The first is related to the search
strategy, as it does not include all possible databases (including Embase) and the grey litera-
ture, which might imply a incompleteness of the results. Secondly, the search was limited to
studies published from 2008 onwards, as it is in the last decade, with the introduction of bio-
logical drugs, where the management and treatment of immune-mediated inflammatory dis-
eases has experienced a major change. Similarly, it was limited to studies conducted in Europe
and North America and published in English and Spanish. Thirdly, the heterogeneity of the
articles included, in terms of diseases, population and methodology could represent a limita-
tion. As a whole, there was a lack of uniformity regarding the measurement tools and thresh-
olds established to formally assess the patient-physician discrepancy. The quality of the studies
included is moderate, what is anyway inherent to the topic of the literature search. In this
regard, a review considering different selection criteria could generate different conclusions.
Nonetheless, the results of this systematic review will allow a better understanding of the areas
and the degree of discrepancy as well as to the determinants that contribute to the discrepancy
between patients and physicians. It is anticipated that a better understanding of these factors
can lead to the development of better strategies for the improvement of immune-mediated
inflammatory diseases management.
In conclusion, this systematic review reveals a significant patient-physician discrepancy
in RA and PsA, being lower for Ps. Based on these results, the physician assessment should
be complemented with a self-report from patient’s perspective, which may facilitate patients
involvement in the management of their disease. This collaborative approach between
patient, physician, and other health professionals can contribute to patient trust in the phy-
sician, allowing patients to express their concerns and thoughts, prioritize their problems,
and discuss with the physician their expectations and goals, what could improve patient
outcomes and increase adherence to treatment. Future research may help to show whether
identifying the discrepancy between patients and physicians, and a better knowledge of
the factors that influence it, may contribute to improve patient care and shared decision-
making.
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